Evidence map›Paper›PMID 36993160›Full record

ArticlebioRxiv : the preprint server for biology2023

Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS

Benjamin C Orsburn

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Benjamin C OrsburnThe Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA, 21205.
Johns Hopkins University · US

Funding

Cellular Signaling in Drug Induced ToxicityR01GM103853 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ORSBURN, BENJAMIN CARL · 2013 to 2022
$3.6M
Drug Phosphorylation and AgingR01AG064908 · NIA · JOHNS HOPKINS UNIVERSITY · PI ORSBURN, BENJAMIN CARL · 2020 to 2023
$2.4M
NIA NIH HHS R01 AG064908NIGMS NIH HHS R01 GM103853
6 · The paper itself

Abstract

Mutations in KRAS are common drivers of human cancers and are often those with the poorest overall prognosis for patients. A recently developed compound, MRTX1133, has shown promise in inhibiting the activity of KRAS

Indexed as

KRASmetabolomicsMRTX1133proteomicsSingle cell proteomics

Identifiers

PMID36993160
PMCPMC10055375
OpenAlexW4360868824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.